D
epressive disorders have traditionally been perceived as acute, episodic conditions. Over the last 2 decades, however, it has been increasingly recognized that many patients experience a long-term, chronic course of depression. Naturalistic studies suggest that between 7% and 12% of depression patients who are prospectively followed up will experience a chronic course (1, 2) . Approximately 20% of naturalistically treated patients with acute major depressive disorder (MDD) will not recover in the first 2 years of their depressive episode (3) , and some 12% of these will not recover within 5 years (1). Further, the incidence of chronicity appears to be high across a range of populations. Community studies indicate a point-prevalence rate for chronic depression of between 2% and 6% (4, 5) . Chronic depressive disorders are also common in psychiatric outpatient samples, where they are frequently comorbid with other conditions (6, 7) . Overall, it has been estimated that chronic depression accounts for 30% to 35% of all cases of depression (5, 8) .
Depression in general (9) and chronic depression in particular (10,11) pose a major public health problem. Patients with chronic depression often have marked impairments in psychosocial and occupational functioning (11) (12) (13) . This reduced functioning is in turn associated with poorer prognosis (10, 14, 15) . Chronic depression is also associated with high rates of health care use (3, 16, 17) and more frequent suicide attempts and hospitalizations (18) .
Accurate detection of chronic depression is particularly important, given the disorder's significant clinical and public health implications. Current evidence suggests, however, that identification rates for acute MDD are poor (19) . Detection rates for chronic depression are likely to be even lower, owing to both patient and physician factors. Patients may adapt to chronic depression, and the condition may eventually be perceived as normal, entrenched, or inappropriate for treatment. Physicians may fail to recognize chronic depression because patients tend not to complain about their depressive symptoms, because it is masked by other comorbid disorders, or because it is seen as a part of the patient's personality. Even if it is correctly identified, the current management of chronic depression appears to be far from optimal. Significant numbers of patients either receive no treatment at all or receive lowintensity treatment, such as subtherapeutic medication dosages (6, 20, 21) . Unsuccessful treatment is likely to demoralize both the patient and the physician.
The literature concerning the current detection and treatment of chronic depression makes for bleak reading. However, encouraging evidence has recently emerged to help dispel the pervading myths that chronic depression has a poor prognosis and is resistant to treatment. Chronic depressive disorders in fact appear to be eminently treatable, provided that the intervention is thorough and vigorous. This article provides a brief update on the diagnosis of chronic depression subtypes and a review of the current evidence base concerning their optimal treatment. It concludes with a section focusing on the translation of this evidence into everyday practice and on some key areas for future research.
Diagnosis of Chronic Depression
The recent literature has discussed 4 main diagnostic types of chronic depression: · MDD, currently in a chronic (defined as 2 years) episode · dysthymic disorder ("pure" dysthymia) · dysthymic disorder with MDD ("double depression") · MDD in incomplete remission MDD, currently in a chronic episode, describes those patients in whom a depressive episode, with full episode criteria, has persisted for at least 2 years. Onset of chronic MDD tends to occur in early to midlife and may continue indefinitely. In a large study of patients with chronic MDD or double depression, mean lifetime illness duration was found to be 17.2 and 15.6 years respectively (21) . Thus, it is not unusual for many patients with chronic depression to experience depression for most of their adult lives and for depression to be perceived as part of their personality. Disconcertingly, 43% of the sample had never received antidepressant pharmacotherapy, and only 20% had received a prior adequate antidepressant trial.
Dysthymic disorder is a lower-grade, chronic (that is, also persisting for more than 2 years) depressive disorder that is usually found in primary care populations. Whereas chronic MDD is characterized by consistently low mood, dysthymia is more sporadic and changeable in nature, tending to have an earlier onset and concomitantly longer periods of illness duration. Dysthymia also appears to be underrecognized and undertreated (6); it is associated with significant psychosocial impairment (9, 12) and high health service use (4) .
Approximately 40% of patients with dysthymia have coexisting MDD (4) or the so-called "double depression" form of chronic depression. These patients frequently return to a dysthymic rather than euthymic state following recovery from their major depressive episode (MDE) (22) .
The final category of chronic depression includes patients with an MDE from which they have only partially recovered, with lack of complete remission persisting for at least 2 years. Several studies have now indicated that residual symptoms following MDD are associated with greatly increased risk of relapse (23, 24) . Such findings suggest that the goal of acute treatment for depression should be the complete remission of symptoms (25, 26) .
In practice, however, the rigid classification and diagnosis of chronic depressive disorders may not prove to be particularly useful. There has been ongoing controversy, for example, concerning the distinction between pure dysthymia and double depression (22, 27) . Research has shown that up to 79% of dysthymic patients will eventually develop an MDE, thereby qualifying for the diagnosis of double depression (8) . More importantly, several studies have shown no significant differences in response rates between patients with pure dysthymia and those with double depression, suggesting that such differentiation may not have significant treatment implications (21, 28) .
Treatment of Chronic Depression: The Evidence Base
Current treatment of chronic depression appears to be far from optimal, despite growing evidence indicating that chronic depressions respond well to several psychiatric interventions.
The following section provides an update on the evidence base for the treatment of chronic depression. We identified key studies in this field via a systematic electronic search of Medline (from January 1, 1966, to November 30, 2001 ) and the Cochrane Library, using the key words chronic, persistent, or long-term depression and treatment, and hand-searched specialist journals and article bibliographies. We included only randomized controlled trials (RCTs) and metaanalyses. Table 1 summarizes the key studies addressing the treatment of chronic depression, excluding pharmacologic studies of the treatment of dysthymia, which have been comprehensively reviewed elsewhere (29, 30) .
Pharmacotherapy Acute treatment.
There is now good evidence from RCTs that standard antidepressant medications are efficacious, safe, and tolerable for the acute treatment of chronic depressive disorders. In particular, the efficacy of antidepressants in the treatment of pure dysthymia (31) (32) (33) (34) and double depression (20, (35) (36) (37) (38) has been demonstrated. For example, Thase and colleagues compared sertraline and imipramine in the treatment of outpatients with dysthymia (n = 410) (33) . Most studies of depression have defined clinical response as > 50% decrease in Hamilton Depression Rating Scale (HDRS) scores at trial endpoint; occasionally, they require concomitant reductions in Clinical Global Impressions (CGI) scales (39) . Full remission has been defined as an HDRS score within the normal range (for example, 8 or less), with CGI improvement scores of 1 or 2 (very much improved or much improved). In the Thase study of dysthymic patients, however, response was defined as a CGI score of 1 or 2, while remission was defined as an HDRS item 1 (depressed mood) score of 0. Both active treatments were found to have significantly better response (59% for sertraline and 64% for imipramine) and remission (50% for sertraline and 44% for imipramine) rates than did placebo (44% response and 28% remission rate) over the 12-week trial. In the sertraline group, fewer dropouts owing to adverse effects were observed. The results of this study are encouraging, particularly since the patients had been suffering from dysthymia for an average of 30 years.
In the acute treatment of chronic depression, antidepressants found to be superior to placebo include selective serotonin reuptake inhibitors (SSRIs) (32) (33) (34) and tricyclic antidepressants (TCAs) (33) , as well as other agents (for example, moclobemide, amisulpride, amineptine, and ritanserin). A metaanalysis has confirmed the equivalent efficacy of TCAs, SSRIs, monoamine oxidase inhibitors (MAOIs), and other agents in the treatment of dysthymia (29, 30) . Overall, acutephase studies have generated intention-to-treat (ITT) response rates in the range of 45% to 55%. These response rates are similar to those seen with antidepressant use in nonchronic depression (40, 41) .
Continuation or Maintenance Treatment. Following response to acute treatment, long-term continuation and maintenance therapy are required to protect patients from further relapses. There have only been a few studies of the long-term treatment of chronic depression (21, 28) .
One of the first systematic studies in this area assessed the efficacy of desipramine in treating patients (n = 129) with pure dysthymia, double depression, and chronic MDD (28) . Full and partial remitters to an initial 10-week, open-label treatment phase were entered into a 16-week continuation phase, after which fully remitted patients were randomized to a 2-year maintenance phase with desipramine or placebo. Relapse rates during the maintenance phase were 52% in the placebo group, compared with 11% in the active drug group. The study was important in that it provided some of the first robust evidence that thorough, long-term treatment of chronic depression does result in enhanced outcome.
A large randomized double-blind multicentre study of continuation therapy has also been conducted (21) . In this study, 635 patients with either chronic MDD or double depression were treated with sertraline, or imipramine, or both. The study design involved an acute 12-week treatment phase, with a crossover to the alternative antidepressant at 12 weeks for nonresponders, followed by a 16-week continuation phase. Patients who were taking imipramine and were still well at the end of the continuation period continued with imipramine for a 76-week maintenance period. Patients who were responding to treatment with sertraline were randomly assigned to either continue with sertraline or undergo placebo substitution.
The results of the acute-treatment phase of this study are encouraging. Both sertraline and imipramine showed equal efficacy in terms of remission (36% for sertraline and 40% for imipramine) and ITT response rates (52% for sertraline and 51% for imipramine), although dropout rates owing to adverse events were significantly higher in the imipramine group. In separate analyses of these data, pharmacologic treatment was also shown to produce relatively rapid improvements in psychosocial impairment (42) and subjective work performance (43) . The continuation phase data from this study are also available for scrutiny and indicate that similar response rates were maintained throughout this 16-week period (44) .
Psychotherapy
It is now well accepted that psychotherapy is an efficacious form of treatment for acute MDD (45) . Intuitively, it seems logical that psychotherapy should also be beneficial in treating chronic depressive disorders. Chronic depression is even more psychosocially disabling than acute MDD (11, 46) , and psychotherapy is likely to benefit the patient by targeting the social and interpersonal difficulties that characterize the condition.
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The Canadian Journal of Psychiatry-Review Paper Three large-sample studies have recently been conducted in primary care patients with chronic depression. In the first, primary care patients with chronic depression or anxiety (n = 181) received short-term counselling (counsellors were described as taking a broadly cognitive or psychodynamic approach) vs "treatment as usual" (50) . There were no significant differences on the Beck Depression Inventory (BDI) scores at 6 or 12 months, although fewer psychotherapy group patients remained BDI cases at 12 months. The generalizability of these results is limited by several factors, however-not least, the study's idiosyncratic definition of chronic depression (a BDI score of ³ 14 and the presence of mild-tomoderate symptoms of depression for 6 months or more). The second study examined primary care patients with either dysthymia or minor depression (n = 241), comparing the effects of 11 weeks of treatment with paroxetine, problemsolving treatment (PST), and placebo (that is, a placebo pill plus clinical management) (51). For dysthymia, remission rates were significantly higher for the groups receiving paroxetine (80%) and PST (57%), compared with the group receiving placebo (44%). A parallel study conducted in patients over age 60 years (n = 415) showed significantly reduced symptoms in the paroxetine group but not the PST group, compared with the placebo group, in both dysthymia and minor depression patients (52) . Interpreting the results of the latter 2 studies is complicated by several factors, including high placebo response rates and differential responses among sites.
Other evidence indicates that patients with chronic depression may require more than a standard course of psychotherapy. In a study of patients with MDD or double depression (n = 84), remission rates following CBT were greater in the MDD group (55% vs 27%) (53) . Interestingly, response to treatment in the 2 groups began to diverge when the frequency of the CBT sessions was reduced, suggesting that psychotherapy for chronic depression may need to be longer or more intensive in nature.
In summary, there remains insufficient evidence at present to conclude whether psychotherapy in isolation is an effective form of treatment for all forms of chronic depression.
However, psychotherapy alone does not appear to be efficacious for dysthymia in primary care populations.
Combination Therapy
The literature concerning the combination of pharmacotherapy and psychotherapy was until recently even more meager, despite growing evidence for the effectiveness of combination therapy in treating acute MDD (54) . Several small trials had provided some early evidence about the effects of combining the 2 treatment modalities (55-57). The most robust of these randomized patients with dysthymia (n = 97) to 1 of 4 treatments: sertraline alone, sertraline plus group cognitive therapy (CT), placebo plus group CT, or placebo alone (56) . Response rates were significantly higher for sertraline combined with CT (71%) and sertraline alone (55%), compared with placebo plus CT (33%) or placebo alone (33%). Although the addition of CT to sertraline did not have a statistically significant effect in terms of response rates, it did in relation to psychological impairment. A pilot study of the effects of combining group psychotherapy and fluoxetine in patients with dysthymia has provided further evidence that psychotherapy may improve interpersonal and psychosocial functioning (57).
These studies have been succeeded, however, by 2 large RCTs of combination therapy for chronic depression. The first, performed by Keller and colleagues, provides the most convincing evidence to date concerning the benefits of combining antidepressants and psychotherapy to treat chronic depression (58). Keller and others compared the efficacy of treatment with nefazodone with the efficacy of the Cognitive Behavioral Analysis System of Psychotherapy (CBASP), an interpersonally orientated version of CBT developed specifically to treat chronic depression (59) . A total of 681 patients with chronic MDD, double depression, or recurrent depression with incomplete remission were randomized to 12 weeks of CBASP monotherapy (16 to 20 sessions), nefazodone monotherapy (maximal dose 600 mg daily), or combination treatment. The study also involved a 4-month continuation or maintenance phase; however, the results of this stage of the study are not yet available for analysis.
Results from the acute phase of the study indicated that antidepressant monotherapy produced quicker results initially and was more efficacious than CBASP alone during the first 4 weeks of treatment. By the end of the 12 weeks, however, both appeared to be equally effective, with response rates of 52% for CBASP and 55% for nefazodone. Response rates in the combination group, however, were significantly better at 85%. Remission rates showed similar trends (33% for CBASP, 29% for nefazodone, and 48% for combination treatment), and psychosocial outcome was also significantly superior in the combined-treatment group (60) . Although patients randomized to nefazodone experienced significantly more adverse events than those receiving CBSAP, rates of discontinuation were similar across the 3 groups.
Criticisms leveled at the Keller study (58) have addressed its lack of a placebo group, and the potential for the study's large sample size to inflate the value of the clinical differences observed (61) . Although the authors rightly respond that placebo response rates tend to be low in patients with chronic depression (62, 63) , this lack does remain a potential limitation. Nevertheless, the study provides timely and important evidence concerning the treatment of chronic depression.
The second notable study in this area is Steiner and others' recent Canadian trial of primary care patients with dysthymia (n = 707) (64) . Patients were randomized to receive sertraline in isolation, sertraline plus interpersonal therapy (IPT), or IPT alone. IPT, which focuses upon interpersonal relationships and improving the patient's communication skills and selfconcept, is becoming an increasingly popular form of psychotherapy for depression. At 6, 12, and 24 months Steiner and others observed that sertraline alone and sertraline combined with IPT were superior to IPT alone (response to treatment was defined as at least a 40% reduction in MontgomeryAsberg Depression Rating Scale scores). A health economic assessment revealed that the combination therapy was no more expensive than drug monotherapy when other health and social care costs were taken into account. The addition of IPT to sertraline was also associated with lower rates of medication discontinuation owing to side effects. The authors concluded that augmenting sertraline treatment with IPT was beneficial, in that it improved the quality of life and coping strategies of patients and reduced their health care services use.
In summary, there is now encouraging evidence that a combination of pharmacotherapy and psychotherapy is an effective, safe, and possibly superior form of treatment for chronic depression. Recently published Canadian guidelines for the treatment of depressive disorders recommend that first-line treatment of chronic depression should consist of concurrent psychotherapy and pharmacotherapy (65) .
Putting the Evidence Into Practice and Future Research
What, then, are the clinical implications of this evidence base?
The following section discusses some of the key clinical issues in this growing field and highlights some important areas of future research.
Detection and Diagnosis
As noted, chronic depressions are frequently comorbid with other conditions (6, 7) . High rates of Axis I disorders-in particular the anxiety conditions-have been reported (66) . For example, pronounced levels of anxiety were observed in the Keller sample (21). Although high baseline anxiety scores did not reduce overall response, they did delay the onset of response to antidepressant treatment (67) . Axis II disorders are also common in chronic depression. Markowitz and colleagues, for example, reported that 85% of a sample of dysthymic patients presented with some form of concurrent personality disorder, particularly the avoidant, self-defeating, dependent, and borderline types (6) . Finally, Axis III medical conditions are known to be highly prevalent in patients with acute depression (68) and are likely to be even more common in chronic depression (69) . There are few treatment studies that have specifically addressed comorbid conditions, but comorbid patients are likely to require longer, more intense, and multimodal therapies (70, 71) . Most previous studies of chronic depression have applied relatively strict exclusion criteria, such as the presence of comorbid Axis I and II disorders. Pragmatic, multidisciplinary trials are now required to ascertain how the more complex comorbid forms of chronic depression respond to treatment in naturalistic settings (72) .
Detection rates for chronic depression appear to be poor, and the presence of comorbidity may exacerbate this problem. The mood disorder may be masked, for example, by a more florid Axis II disorder. Incomplete remission of MDD may be missed if symptom outcome measures are not used. For patients with double depression, return to baseline dysthymia is not an adequate treatment goal, since many of these patients can have full remission of symptoms, even with antidepressant treatment alone (44) . In addition, once the chronicity of a depressive episode is identified, it may not be paramount to determine exactly which diagnostic subtype it represents, because the subtypes do not appear to differ greatly in terms of treatment response (21, 28) .
Mode of Treatment
The optimal management of chronic depression is likely to require that a range of treatment options be considered and that those selected often be implemented in a stepwise fashion. Treatment algorithms for chronic and refractory depression have been proposed (73) (74) (75) , although their effectiveness in clinical settings has not yet been evaluated. There is little evidence to suggest that any single type of antidepressant is superior to another in the treatment of chronic depression (29, 30, 75) , although more than one medication trial may be required before an optimal regimen is found (76) . The longterm tolerability of a selected drug should be an important consideration, especially because lengthy or indeed indefinite maintenance treatment periods may be required. Given that many chronic depressions are treatment-refractory or show incomplete remission with treatment, augmentation and combination strategies may be required to optimize medication response (75, 77) . To our knowledge, no previous trials have addressed the effects of tailoring medication regimes in patients with chronic depression. Useful future research would focus upon the effectiveness of tailored pharmacologic management, with special emphasis on treatment tolerability, adverse effects, adherence to drug regimen, and frequent monitoring and reassessment. There may also be several other somatic treatment options, including light therapy, electroconvulsive therapy, or novel interventions such as vagus nerve stimulation or repetitive transcranial magnetic stimulation (75) . The evidence concerning the efficacy of these options in treating chronic depression is, however, still scant.
There is insufficient evidence at present to judge whether psychotherapy in isolation is an effective treatment for chronic depression (and psychotherapy alone is not recommended for dysthymic disorder owing to evidence that it is not efficacious [56] ). Adding psychotherapy to pharmacotherapy is likely to be of significant benefit in the treatment of chronic depression (58) . Psychotherapies shown to be effective include CBT, IPT, and the more specific CBASP. Early evidence indicates that patients with chronic and refractory depression may require a more intensive course of psychotherapy than is currently standard (53, 71) .
As previously noted, chronic depression is associated with marked impairment (11) (12) (13) , and successful pharmacologic treatment appears to improve psychosocial functioning (78) . Chronic depression also has profound effects upon occupational functioning (13) , and preliminary evidence suggests that effective treatment improves subjective work performance (43) . However, we are not aware of any studies that have examined the effects of systematically treating the occupational dysfunction associated with chronic depression. Occupational therapy may provide a useful adjunctive treatment by focusing upon improving the problem-solving skills, interpersonal skills, and coping mechanisms damaged by chronic illness (79).
Long-Term Management
Important gaps remain in our knowledge concerning the optimal maintenance treatment for chronic depression. Current evidence supports a multiyear maintenance phase, particularly in patients who have experienced previous episodes, where risk from relapse may be greater (80) . However, there are no data available for the effectiveness of maintenance treatments beyond 2 years. The medication dosages that were effective in the acute-treatment phase should be maintained in the long-term treatment of chronic depression (81) . Medication adherence is a significant issue in this maintenance period. Poor adherence has been related to worse outcome in the long-term management of depression in some (82), but not all (83) studies. Ensuring patient adherence in the acute phases of treatment has proved challenging. Maintaining adherence in long-term treatment may be easier, because patients are likely to be feeling the benefits of treatment or experiencing fewer side effects as treatment regimens are tailored. Conversely, persuading patients to continue taking medication when they feel well holds its own challenges. Over and above simple education, it is likely to be beneficial to fully involve patients as collaborators in their treatment and to share decision making with them (84) .
Maintenance psychotherapy may be important to maintain patients' feelings of motivation and self-efficacy, to prepare patients for setbacks should they occur, and to enhance medication adherence. However, maintenance-phase psychotherapy is only beginning to be studied (81, 85, 86) ; there is as yet no evidence available about the optimal "dosage" of maintenance psychotherapy for chronic depression.
Conclusions
Chronic depressive disorders are highly prevalent in both community and hospital populations and result in substantial disability for the individual and society. In the past, chronic depression was thought to be embedded in personality disorder, to have limited response to treatment, and to show a poor prognosis (87, 88) . As we currently understand it, chronic depression includes several diagnostic subtypes. A larger evidence base on treatment for chronic depression has accumulated (although "depressive personality disorder" is controversially being considered for inclusion in future editions of the DSM). While early work in this field was limited by methodological problems, several well-designed, systematic studies have now been performed. Broadly, these indicate that chronic depression responds favourably to antidepressants during the acute and maintenance phases of treatment, provided that the medication treatment is both thorough and intensive. An effective new approach to the treatment of chronic depression combines psychotherapy and antidepressants. Further research is now required to ascertain whether combined and individualized treatment regimens are effective in naturalistic clinical settings.
Although our knowledge concerning the treatment of chronic depression has developed rapidly, changes in clinical practice have been slower to evolve. Evidence indicates that chronic depressions remain poorly diagnosed and suboptimally treated. The challenge of the future is to dispel the myths that surround chronic depression and to implement this growing evidence base in clinical practice while continuing to address the gaps that remain in our understanding of its treatment.
Only then can we begin to reduce the significant personal and societal burden that results from this highly prevalent condition. Résultats : Les troubles dépressifs chroniques répondent bien aux interventions pharmacologiques régulières aux phases aiguë et d'entretien du traitement. Les psychothérapies régulières ne sont pas efficaces à elles seules pour la dépression chronique (surtout pour la dysthymie). Des données probantes récentes indiquent que le traitement combinant psychothéra-pie et médicaments peut être supérieur à l'un de ces deux traitements administré seul.
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Conclusions :
Les troubles dépressifs chroniques peuvent faire l'objet de traitement, pourvu que l'intervention soit complète et intensive. Nos connaissances sur le traitement optimal de la dépression chronique se sont développées rapidement, mais les changements de la pratique clinique sont plus lents à suivre. Il faut d'autres recherches pour évaluer l'efficacité des interventions multimodales sur la dépression chronique dans des cadres plus ordinaires.
